').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();
Glenmark Pharmaceuticals Launches Drug To Treat Heart Failure In India
Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF
Topics
Glenmark Pharmaceuticals | Pharma Companies | Heart Failure
Glenmark Pharmaceuticals on Tuesday said it has launched sacubitril and valsartan combination tablets in India for treatment of heart failure.
The prescription drug has been launched under brand 'Sacu V' and is priced at Rs 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26mg), Rs 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and Rs 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan 103 mg), Glenmark said in a regulatory filing.
Glenmark Pharmaceuticals EVP & Business Head India Formulations, Alok Malik said Sacu V is an advanced and affordable treatment option, which has been shown to reduce the risk of cardiovascular death or heart failure hospitalisation and to improve symptoms associated with heart failure with reduced ejection fraction (HFrEF).
The company said Sacu V must be taken twice daily under doctor's prescription. Its approved indication is to reduce the risk of cardiovascular related deaths and hospitalisations for patients with chronic heart failure with HFrEF.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
First Published: Tue, January 17 2023. 14:41 IST
RECENT NEWS
Stablecoin The Future Of Currency?
The payments system is undergoing a quiet but consequential shift. What was once the exclusive preserve of central banks... Read more
BoE Loosens Capital Rules
The Bank of England has taken a significant step towards easing post-crisis regulation by lowering its estimate of the c... Read more
Monzo Looks For US Banking License
Monzo is preparing a renewed push to secure a US banking licence, four years after abandoning its first attempt when tal... Read more
Crypto Firms Push Into US Banking
America’s cryptocurrency companies are scrambling to secure a foothold in the country’s traditional banking system, ... Read more
Parallel Banking: Stablecoins Are Now Global
Parallel Banking: How Stablecoins Are Building a New Global Payments SystemStablecoins—digital currencies pegged to tr... Read more
JPMorgan Deploys AI Chatbot To Revolutionize Research And Productivity
JPMorgan has deployed an AI-based research analyst chatbot to enhance productivity among its workforce, with approximate... Read more